Malignancy-associated dyslipidemia

Open Cardiovascular Medicine Journal

Volumn 5, Issue SPEC. ISSUE, 2011, Pages 35-40

  Bielecka Da̧browa, Agata ^a   Hannam, Simon ^b   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cholesterol; Dyslipidemia; Statins

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ASPARAGINASE; BEXAROTENE; CHOLESTEROL; CORTICOSTEROID; EXEMESTANE; FENOFIBRATE; GESTAGEN; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE; TAMOXIFEN; TRIACYLGLYCEROL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CARCINOGENICITY; CARDIOVASCULAR RISK; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; GENETIC SUSCEPTIBILITY; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPEMIA; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; MUTAGENICITY; NEOPLASM; PHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SIDE EFFECT; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80355142786     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010035     Document Type: Article

References (76)

1. Patel PS, Shah MH, Jha FP, et al. Alterations in plasma lipid pro-file patterns in head and neck cancer and oral precancerous conditions. Indian J Cancer 2004; 41: 25-31.
2. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 1998; 83: 379-84.
3. Simo CE, Orti LA, Sena FF, Contreras BE. Blood cholesterol in patients with cancer. Ann Med Intern 1998; 15: 363-6.
4. Allampallam K, Dutt D, Nair C, et al. The clinical and biologic significance of abnormal lipid profiles in patients with myelodys plastic syndromes. J Hematother Stem Cell Res 2000; 9: 247-55.
5. Summerfield FW, Tappel AL. Determination of fluorescence quenching of the environment of DNA cross-links made by malondialdehyde. Biochim Biophys Acta 1983; 740: 185-9.
6. Marnett LJ, Tuttle MA. Comparison of the mutagenecity of malondialdehyde and the side-products formed during its chemical synthesis. Cancer Res 1980; 40: 276-82.
7. Stepsenwol J. Carcinogenic effect of cholesterol in mice. Proc Soc Exp Biol Med 1966; 121: 168-71.
8. Takatani O, Okumoto T, Kosano H. Genesis of breast cancer in Japanese: a possible relationship between sex hormone-binding globulin (SHBG) and serum lipid components. Breast Cancer Res Treat 1991; 18: 527-9.
9. Regnstrom J, Nisson J, Toruvall P, Laudou C, Hamsten A. Susceptibility to low-density lipoproteins oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1883-6.
10. Babiy AV, Gebicki JM, Sullivan DR, Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharma- col 1992; 43: 995-1001.
11. Chander R, Kapoor NK. High-density lipoprotein is a scavenger of superoxide anions. Biochem Pharmacol 1990; 40: 1663-5.
12. Swyer GIM. The cholesterol content of normal and enlarged prostates. Cancer Res 1942; 2: 372-5.
13. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008; 9: 259-1266.
14. McKeown N. Antioxidants and breast cancer. Nutr Rev 1999; 57: 321-4.
15. Wesseling C, Antich D, Hogstedt C, Rodriguez AC, Ahlbom A. Geographical differences of cancer incidence in Costa Rica in relation to environmental and occupational pesticide exposure. Int J Epidemiol 1999; 28: 365-74.
16. Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE. Association of dietary intake of fat and fatty acids with risk of breast cancer. J Am Med Assoc 1999; 281: 914-20.
17. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 2001; 34: 71-6.
18. Alexopoulos CG, Blatsios B, Avgerinos A. Serum lipids and lipo protein disorders in cancer patients. Cancer 1987; 60: 3065-70.
19. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 1998; 83: 379-84.
20. Favrot MC, Dellamonica C, Souillet G. Study of blood lipids in 30 children with a malignant hematological disease or carcinoma. Biomed. Pharmacother 1984; 38: 55-9.
21. Carbo N, Costelli P, Tessitore L, et al. Anti-tumour necrosis factor treatment interferes with changes in lipid metabolism in a tumour cachexia model. Clin Sci 1994; 87: 349-55.
22. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-58.
23. Shah FD, Shukla SN, Shah PM, Patel HR, Patel PS. Significance of alterations in plasma lipid profile levels in breast cancer. Integr Cancer Ther 2008; 7: 33-41.
24. Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. Eur J Gynaecol Oncol 2008; 29: 158-61.
25. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective basel study. Am J Clin Nutr 2000; 71: 569-74.
26. Feinleib M. Review of epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res 1983; 43: 2503S-7S.
27. Kark JD, Smith AH, Switzere BR, Hames CG. Retinol, carotene, and the cancer/cholesterol association. Lancet 1981; 1: 1371-2.
28. Kark JD, Smith AH, Hames CG. Serum retinol and the inverse relationship between serum cholesterol and cancer. BMJ 1982; 284: 152-4.
29. Schatzkin A, Hoover RN, Taylor PR, et al. Site-specific analysis of total serum cholesterol and incident cancers in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. Cancer Res 1988; 48: 452-8.
30. Chyou PH, Nomura AM, Stemmermann GN, Kato I. Prospective study of serum cholesterol and site-specific cancers. J Clin Epidemiol 1992; 45: 287-92.
31. Rose G, Shipley MJ. Plasma lipids and mortality: a source of Error. Lancet 1980; 1: 523-6.
32. Yang X, So WY, Ko GTC, Ma RCW, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008; 179: 427-37.
33. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006.
34. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
35. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195-201.
36. Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. Br J Haematol 2009; 145: 84-6.
37. Ridola V, Buonuomo PS, Maurizi P, et al. Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer 2008; 50: 378-80.
38. Nakagawa M, Kimura S, Fujimoto K, et al. A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. Ther Apher Dial 2008; 12: 509-13.
39. Utsumi T, Kobayashi N, Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 2007; 14: 194-9.
40. Namiki M, Ueno S, Kitagawa Y, et al. Hormonal therapy. Int J Clin Oncol 2007; 12: 427-32.
41. Bulusu NV, Lewis SB, Das S, Clayton WE, Jr. Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology 1982; 20: 147-50.
42. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Jr. Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983; 57: 262-7.
43. Fahraeus L, Sydsjo A, Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 1986; 45: 503-6.
44. Grönroos M, Lehtonen A. Effect of high dose progestin on serum lipids. Atherosclerosis 1983; 47: 101-5.
45. Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988; 12: 307-10.
46. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534-9.
47. Wasan KM, Ramaswamy M, Haley J, Dunn BP. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer. J Pharm Sci 1997; 86: 876-9.
48. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 2003; 79: 11-6.
49. Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000; 11: 1067-9.
50. Artac M, Sari R, Altunbas H, Karayalcin U. Asymptomatic acute pancreatitis due to tamoxifen-induced severe hypertriglyceridemia in a patient with diabetes mellitus and breast cancer, J Chemother 2002; 14: 309-11.
51. Athyros VG, Giouleme OI, Nikolaidis NL, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis, J Clin Gastroenterol 2002; 34: 472-5.
52. Mikhailidis DP, Ganotakis ES, Georgoulias VA, Vallance DT, Winder AF. Tamoxifen-induced hypertriglyceridaemia: seven case reports and suggestions for remedial action. Oncol Rep 1997; 4: 625-8.
53. Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig 2006; 26: 297-302.
54. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620-35.
55. Monnier A. Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther 2006; 6: 1653-62.
56. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health andother safety parameters: results of an open, randomised, multicentre study of letrozole, exemestane and anastrozole in healthypostmenopausal women. Eur J Cancer 2007; 43: 2523-31.
57. Jakesz R. The adjuvant endocrine treatment revolution: focus on anastrozole. Expert Opin Drug Metab Toxicol 2006; 2: 301-12.
58. Filippatos FD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35: 175-84.
59. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409-18.
60. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med 2008; 121: 302-9.
61. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inihibition of the proteasome, independent of hydoxylmethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96: 7797-802.
62. Baigent C, Keech A, Kearney PM, et al. Cholesterol Freatment Trialists' (CTT) Collaborators: efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
63. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-17.
64. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
65. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and meta-analysis. Int J Cancer 2007; 120: 833-43.
66. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopusal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
67. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16: 624-9.
68. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets 2006; 6: 15-37.
69. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009; 25: 1995-2005.
70. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol-lowering therapy and cell membranes: stable plaque at the expense of unstable membranes? Arch Med Sci 2009; 5: 289-95.
71. Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009; 13: 541-50.
72. Boncler M, Gresner P, Nocun M, et al. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta 2007; 1770: 1651-9.
73. cibior-Bentkowska D, Skrzycki M, Podsiad M, Czeczot H. Changes of the glutathione enzymatic redox system in human gastrointestinal tract tumours. Arch Med Sci 2009; 5: 500-5.
74. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Macie jewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009; 15: MS12-23.
75. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
76. Stawiarska-Piȩta B, Birkner E, Szaflarska-Stojko E, et al. The influence of diet supplementation with methionine on the pathomorphological changes of rabbit organs in experimental atherosclerosis. Arch Med Sci 2008; 4: 371-9